How deadly is the 'deadly quartet'? A post-CABG evaluation

Journal of the American College of Cardiology

Volumn 36, Issue 4, 2000, Pages 1159-1165

  Sprecher, Dennis L ^a   Pearce, Gregory L ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Cleveland Clinic Foundation ^*

Author keywords

[No Author keywords available]

Indexed keywords

TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLUSTER ANALYSIS; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; SEX DIFFERENCE; SURVIVAL;

AGED; CAUSE OF DEATH; COMPARATIVE STUDY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DIABETES MELLITUS; FEMALE; HOSPITAL MORTALITY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGE; OBESITY; OHIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE;

EID: 0033809837     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00867-6     Document Type: Article

References (40)

1. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
2. Banting lecture 1988. Role of insulin resistance in human disease
3. Clustering of cardiovascular risk factors: Targeting high-risk individuals
4. Impact of multiple risk factor profiles on determining cardiovascular disease risk
5. Diabetes and cardiovascular disease. The 'common soil' hypothesis
6. Diabetes and cardiovascular disease. The Framingham Study
7. Clustering of metabolic factors and coronary heart disease
8. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit?
9. Lipoproteins, lipases, and the metabolic cardiovascular syndrome
10. Abdominal obesity as important component of insulin-resistance syndrome
11. Variations in mortality by weight among 750,000 men and women
12. Management of dyslipidemia in adults with diabetes. American Diabetes Association
13. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
14. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
15. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)
16. Influence of diabetes and mammary artery grafting on survival after coronary bypass
17. Diabetes mellitus and morbidity and mortality risks after coronary artery bypass surgery
18. Differences in the long term mortality of the diabetic and non-diabetic populations in the Coronary Angioplasty vs Bypass Investigation (CABRI)
19. Epidemiology of triglycerides: A view from Framingham
20. Regression models and life tables
21. The efficiency of Cox's likelihood function for censored data
22. Insulin resistance and atherosclerosis. Common roots for two common diseases?
23. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study
24. Better outcome for women compared with men undergoing coronary revascularization: A report from the Bypass Angioplasty Revascularization Investigation (BARI)
25. Guidelines for healthy weight
26. Overweight, obesity, coronary heart disease, and mortality: The W.O. Altwater Memorial Lecture, 1980
27. Obesity, atherosclerosis, and coronary artery disease
28. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study
29. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994
30. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group
31. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
32. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1
33. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
34. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
35. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group
36. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
37. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
38. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
39. Effects of aggressive cholesterol lowering and low-dose anticoagulatlon on clinical and angiographic outcomes in patients with diabetes: The Post Coronary Artery Bypass Graft Trial